Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate September 30, 2025
Avenzo collects another $60M for two small molecules and two ADCs licensed from China September 22, 2025
